Trials / Completed
CompletedNCT05803902
An Evaluation of 9MW1911 Injection in Healthy Subjects
A Randomized, Double-blind, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 9MW1911 Injection in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is a randomized, double-blind, dose-escalating phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of 9MW1911 injection in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Experimental drug 9MW1911 | Experimental drug administered with IV infusion |
| DRUG | Placebo | Placebo administered with IV infusion |
Timeline
- Start date
- 2021-12-15
- Primary completion
- 2023-03-06
- Completion
- 2023-03-06
- First posted
- 2023-04-07
- Last updated
- 2025-12-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05803902. Inclusion in this directory is not an endorsement.